Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
Primary central nervous system lymphoma is a rare but aggressive brain malignancy. It is associated with poor prognosis even with the current standard of care. The aim of this study was to evaluate the effect and tolerability of blood–brain barrier disruption treatment combined with high-dose treatm...
Main Authors: | Hanne K. Kuitunen, Aino L. K. Rönkä, Eila M. Sonkajärvi, Juha-Matti Isokangas, Marja Pyörälä, Kari A. A. Palosaari, Anna S. Jokimäki, Anu E. Partanen, Harri J. Littow, Merja A. Vakkala, Esa J. Jantunen, Mirja E. Huttunen, Katja J. Marin, Annikki M. K. Aromaa-Häyhä, Päivi K. Auvinen, Tuomas Selander, Inka K. Puhakka, Outi M. Kuittinen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/4/1341 |
Similar Items
-
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma
by: Julia Wendler, et al.
Published: (2022-09-01) -
Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
by: Alexander Baraniskin, et al.
Published: (2021-05-01) -
Treatment outcome and prognostic factors in PCNSL
by: Pimjai Niparuck, et al.
Published: (2019-06-01) -
High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers
by: Jingjing Ma, et al.
Published: (2023-10-01) -
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial
by: Lisa K Isbell, et al.
Published: (2023-08-01)